Table 2.
Standardized Cumulative Incidence of CKD in Treated Primary Aldosteronism and Essential Hypertension.
| Cumulative Incidence Times | PA – MR Antagonists | PA – Surgical Adrenalectomy | Essential Hypertension | Difference in Incident CKD (PA MRA – PA Surgery) | Difference in Incident CKD (PA MRA – EH) | Difference in Incident CKD (EH – PA Surgery) |
|---|---|---|---|---|---|---|
| 2-Year Cumulative CKD Incidence (per 100 persons) | ||||||
| Unadjusted (95% CI) | 12.2 (9.9, 14.4) | 3.7 (1.5, 5.9) | 7.8 (7.4, 8.2) | 8.5 (5.4, 11.6) | 4.4 (2.1, 6.6) | 4.1 (1.9, 6.3) |
| Adjusted (95% CI)* | 12.1 (9.9, 14.2) | 5.6 (2.3, 8.7) | 7.7 (7.3, 8.1) | 6.5 (2.7, 10.4) | 4.3 (2.2, 6.5) | 2.2 (−1.1, 5.4) |
| 5-Year Cumulative CKD Incidence (per 100 persons) | ||||||
| Unadjusted (95% CI) | 28.3 (23.6, 32.8) | 9.3 (3.8, 14.4) | 18.9 (18.2, 19.5) | 19.1 (12.1, 26.1) | 9.5 (4.9, 14.1) | 9.6 (4.3, 14.9) |
| Adjusted (95% CI)* | 27.9 (23.6, 31.9) | 14.0 (6.2, 21.1) | 18.9 (18.2, 19.5) | 13.9 (5.3, 22.4) | 9.0 (4.8, 13.2) | 4.9 (−2.6, 12.3) |
| 10-Year Cumulative CKD Incidence (per 100 persons) | ||||||
| Unadjusted (95% CI) | 39.0 (33.0, 44.6) | 13.4 (5.6, 20.6) | 26.7 (25.8, 27.6) | 25.6 (16.2, 35.1) | 12.4 (6.5, 18.2) | 13.3 (5.7, 20.8) |
| Adjusted (95% CI)* | 38.3 (33.0, 43.2) | 20.4 (9.6, 30.0) | 26.9 (26.1, 27.8) | 17.9 (6.5, 29.2) | 11.4 (6.2, 16.5) | 6.5 (−3.7, 16.7) |
CKD = chronic kidney disease; PA = primary aldosteronism; MR = mineralocorticoid receptor; MRA = mineralocorticoid receptor antagonist; EH = essential hypertension.
*
Standardized to the distributions at the time of study entry in our cohort for the following variables: age, sex, race/ethnicity, diabetes mellitus, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, pre-existing cardiovascular disease, and systolic blood pressure.